We are live on ! Find out more
VERA icon

Vera Therapeutics
VERA

84 hedge funds and large institutions have $538M invested in Vera Therapeutics in 2023 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 38 increasing their positions, 15 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

153% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 15

113% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 8

11% more funds holding

Funds holding: 76 → 84 (+8)

2.44% more ownership

Funds ownership: 86.14% → 88.58% (+2.4%)

12% less capital invested

Capital invested by funds: $612M → $538M (-$73.7M)

29% less funds holding in top 10

Funds holding in top 10: 7 → 5 (-2)

Holders
84
Holders Change
+8
Holders Change %
+10.53%
% of All Funds
1.33%
Holding in Top 10
5
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-28.57%
% of All Funds
0.08%
New
17
Increased
38
Reduced
15
Closed
8
Calls
$364K
Puts
–
Net Calls
+$364K
Net Calls Change
+$2M

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$19.7M
2
WP
Woodline Partners
California
+$13.9M
3
Axa
Axa
France
+$4.65M
4
ACM
Altium Capital Management
New York
+$3.67M
5
BlackRock
BlackRock
New York
+$3.23M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$18.7M
2
CG
Carlyle Group
District of Columbia
-$16.8M
3
Millennium Management
Millennium Management
New York
-$5.36M
4
EP
Eversept Partners
New York
-$4.5M
5
O
OrbiMed
New York
-$4.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
CC
1
Commodore Capital
New York
$74.7M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$74.7M -$18.7M -1,090,194 -17%
SI
3
Sofinnova Investments
California
$47.5M – – –
KCM
4
Kynam Capital Management
New Jersey
$40.5M -$754K -43,947 -1%
WP
5
Woodline Partners
California
$35.1M +$13.9M +808,910 +46%
BlackRock
6
BlackRock
New York
$32.3M +$3.23M +188,284 +9%
State Street
7
State Street
Massachusetts
$23.7M +$19.7M +1,151,097 +200%
Vanguard Group
8
Vanguard Group
Pennsylvania
$21.6M +$2.3M +134,125 +9%
O
9
OrbiMed
New York
$20.8M -$4.1M -238,685 -14%
EP
10
Eversept Partners
New York
$20.3M -$4.5M -262,462 -15%
CG
11
Carlyle Group
District of Columbia
$19.7M -$16.8M -978,682 -40%
Pictet Asset Management
12
Pictet Asset Management
Switzerland
$16.8M +$21M +1,226,147 New
Morgan Stanley
13
Morgan Stanley
New York
$12.5M -$914K -53,299 -6%
IBT
14
International Biotechnology Trust
United Kingdom
$10.4M -$3.72M -216,872 -22%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$10.1M +$1.51M +87,875 +14%
Goldman Sachs
16
Goldman Sachs
New York
$5.76M +$2.3M +134,311 +47%
Invesco
17
Invesco
Georgia
$5.36M +$1.99M +116,171 +42%
SAM
18
Sectoral Asset Management
Quebec, Canada
$4.9M +$94.2K +5,493 +2%
ACM
19
Altium Capital Management
New York
$4.57M +$3.67M +213,681 +178%
AI
20
Alphabet Inc
California
$4.13M – – –
Northern Trust
21
Northern Trust
Illinois
$4.05M +$310K +18,041 +7%
N
22
Nuveen
North Carolina
$3.99M +$2.12M +123,432 +74%
Axa
23
Axa
France
$3.72M +$4.65M +270,993 New
Charles Schwab
24
Charles Schwab
California
$3.66M +$3.03M +176,473 +195%
PIM
25
Platinum Investment Management
Australia
$2.75M -$161K -9,398 -4%
1
2 3 4

VERA Hedge Fund Activity: Q3 2023 in Review

84 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Vera Therapeutics (VERA) for Q3 2023, worth a combined $538M — down 12% from $612M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new VERA positions and 8 closed out — a net gain of 9 holders — while 38 added to existing stakes and 15 trimmed.

The largest buyer was State Street, adding an estimated $19.7M. The largest seller was Fidelity Investments, cutting an estimated $18.7M.

  • 84 institutional investors held Vera Therapeutics (VERA) as of Q3 2023, up from 76 in Q2 2023.
  • Funds reported $538M of Vera Therapeutics stock for Q3 2023, down 12% quarter-over-quarter.
  • 17 funds opened new Vera Therapeutics positions in Q3 2023 and 8 closed out, a net change of +9 holders.
  • The largest Vera Therapeutics buyer in Q3 2023 was State Street, an estimated $19.7M added.
  • The largest Vera Therapeutics seller in Q3 2023 was Fidelity Investments, an estimated $18.7M sold.

Based on aggregated 13F filings for Q3 2023.